Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/24/18 (What's New)

Summary

  • Voxilaprevir is an NS3/NS4A protease inhibitor
  • Voxilaprevir, coformulated with sofosbuvir and velpatasvir, is approved by the FDA for 12-week retreatment of genotypes 1-6 HCV after previous failure of an NS5A inhibitor–containing regimen and genotypes 1a or 3 after previous failure of a sofosbuvir-containing regimen[FDA Sofosbuvir Velpatasvir Voxilaprevir]

Action required